Peak Plasma Concentrations After Oral Morphine

Slides:

Advertisements

Similar presentations

Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain Tarja Heiskanen, MD, PhD, Kaarina Langel, MSc, Teemu Gunnar, BSc, MSc, Pirjo.

Advertisements

Neurotoxicity from Chronic Opioid Therapy After Successful Palliative Treatment for Painful Bone Metastases Andrew Broadbent, BMedSc, MBChB, FRACP, FAChPM,

High Opioid Costs in Argentina

Bile Acid Synthesis in Humans Has a Rapid Diurnal Variation That Is Asynchronous With Cholesterol Synthesis Cecilia Gälman, Bo Angelin, Mats Rudling

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Steady-State Kinetics and Dynamics of Morphine in Cancer Patients

A Comparison of the Pharmacokinetics, Clinical Efficacy, and Tolerability of Once-Daily Tramadol Tablets with Normal Release Tramadol Capsules Bhavesh.

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

Possible exacerbation of adrenal suppression from intrathecal morphine in a patient receiving pulsed dexamethasone for multiple myeloma Arun Rajagopal,

The opportunity for collaborative care provision: the presence of nursing home/hospice collaborations in the U.S. states Susan C. Miller, PhD, Vincent.

Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Combination Analgesic Efficacy

Opioid Metabolites Journal of Pain and Symptom Management

Elevated Serum Vitamin B12 Levels Associated With CRP as a Predictive Factor of Mortality in Palliative Care Cancer Patients Philippe Geissbühler, MD,

International Journal of Cardiology

Bettina N. Nielsen, MSc, Gitte Aagaard, RN, Steen W

Urine Acidification After Ammonium Chloride

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative.

Persistent PORT-A-CATH®-Related Fistula and Fibrosis in a Breast Cancer Patient Successfully Treated With Local Ozone Application Bernardino Clavo, MD,

Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system Ashley M.

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

The symptoms of dying children

Morphine with Dextromethorphan

David Clark, PhD, Michael Wright, PhD

Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia Sally L Collins, BSc, R.Andrew Moore, DSc, Henry J McQuay, DM,

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Myra Glajchen, DSW, Marilyn Bookbinder, PhD, RN

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study M.A.

Gender differences in the perception of chest pain

Managing Medicines for Patients Dying at Home: A Review of Family Caregivers' Experiences Eleanor Wilson, PhD, MSc, BA, Glenys Caswell, PhD, MRes, BA,

R.J.Ni Mhuircheartaigh, R.A. Moore, H.J. McQuay

Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain Tarja Heiskanen, MD, PhD, Kaarina Langel, MSc, Teemu Gunnar, BSc, MSc, Pirjo.

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

A Comparative Review of Palliative Care Development in Six Countries Represented by the Middle East Cancer Consortium (MECC) Amanda Bingley, PhD, David.

The Role of a Low-Dose Ketamine-Midazolam Regimen in the Management of Severe Painful Crisis in Patients With Sickle Cell Disease Qutaiba A. Tawfic,

Pharmacokinetics and safety of multiple oral doses of sustained-release 4- aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord.

Prevalence and Characteristics of Breakthrough Pain in Cancer Patients Admitted to a Hospice Giovambattista Zeppetella, BSc (Hons), MRCGP, Catherine.

Pharmacokinetics of Phenobarbital in Microenema Via Macy Catheter Versus Suppository Y.W. Francis Lam, PharmD, FCCP, Ansom Lam, MD, Brad Macy, RN, BSN,

Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer.

Improving Access to Opioid Analgesics for Palliative Care in India

Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long- Term Morphine Treatment Gertrud Andersen, MD, Lona L Christrup, PhD, Per.

A Pharmacokinetic and Tolerability Evaluation of Two Continuous Subcutaneous Infusion Systems Compared to an Oral Controlled-Release Morphine Pia Mikkelsen.

T. Iirola, S. Vilo, R. Aantaa, M. Wendelin-Saarenhovi, P. J

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

U.S. Hospice Benefits Journal of Pain and Symptom Management

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients.

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients Ola.

Volume 117, Issue 1, Pages (July 1999)

Karla T. Washington, PhD, Christopher R. Rakes, PhD

Knowledge and Attitudes of Italian Medical Staff Towards the Approach and Treatment of Patients in Pain Marco Visentin, MD, Leonardo Trentin, MD, Roberto.

Georg Matheis, MD, Friedhelm Beyersdorf, MD

Providing Constant Analgesia with OROS® Hydromorphone

Cognitive performance in patients after carotid endarterectomy

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Physical Function in Patients with Cancer

Morphine Bioavailability from a Topical Gel Formulation in Volunteers

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Gerd Inger Ringdal, PhD, Marit S Jordhøy, MD, Stein Kaasa, PhD

Helping Patients with Advanced Cancer Live with Concerns About Eating: A Challenge for Palliative Care Professionals Jane Hopkinson, PhD, RGN, Jessica.

The bioavailability of morphine applied topically to cutaneous ulcers

How Should End-of-Life Advance Care Planning Discussions Be Implemented According to Patients and Informal Carers? A Qualitative Review of Reviews Alex.

Cancer Symptom Clusters: A Validation Study

Injected Morphine in Postoperative Pain

Nausea and Vomiting Remain a Significant Clinical Problem

Patient-Controlled Analgesia for Children at Home

Presentation transcript:

Peak Plasma Concentrations After Oral Morphine SallyL Collins, BSc, ClaraC Faura, PhD, R.Andrew Moore, DSc, HenryJ McQuay, DM Journal of Pain and Symptom Management Volume 16, Issue 6, Pages 388-402 (December 1998) DOI: 10.1016/S0885-3924(98)00094-3

Fig. 1 Values for dose-corrected Cmax (left panel) and Tmax (right panel) for oral morphine by type of formulation (immediate-release, controlled-release, and once-daily). Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 2 Values for dose-corrected Cmax (left panel) and Tmax (right panel) for immediate-release and controlled-release oral morphine according to type of subject in the original study. Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 3 Values for dose-corrected Cmax (left panel) and Tmax (right panel) for immediate-release and controlled-release oral morphine according to dosing regimen and also showing type of subject in the original study. Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 4 Values for dose-corrected Cmax (left panel) and Tmax (right panel) for immediate-release oral morphine according to specific formulation and also showing type of subject in the original study. Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 5 Values for dose-corrected Cmax for controlled-release oral morphine according to brand. The results for multiple dose (upper panel) and those for single-dose studies (lower panel) are also divided according to type of subject (patients: white; healthy volunteers: gray). The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 6 Values for Tmax for controlled-release oral morphine according to brand. The results for multiple doses (upper panel) and those for single-dose studies (lower panel) are also divided according to type of subject (patients: white; healthy volunteers: gray). The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 7 Values for dose-corrected Cmax (left panel) and Tmax (right panel) for single doses of controlled-release and once-daily oral morphine in healthy volunteers according whether the subjects were fed or fasted. Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)

Fig. 8 Values for dose-corrected Cmax for immediate-release (left panel) and controlled-release (right panel) oral morphine according to whether the samples were analyzed by high performance liquid chromatography (HPLC), radioimmunoassay (RIA), or another method (Other). Black diamonds show the weighted mean values for each group. The size of the symbol is proportional to the number of subjects in the original study Journal of Pain and Symptom Management 1998 16, 388-402DOI: (10.1016/S0885-3924(98)00094-3)